Roche and Genentech officially opened their new innovation center in Allston, Boston on Thursday, a research campus built inside a mixed-use development at Harvard's Enterprise Research Campus that will focus on cardiovascular, renal and metabolism diseases alongside artificial intelligence and data science work. Boston Mayor Michelle Wu, Massachusetts Governor Maura Healey and U.S. Representative Jake Auchincloss joined Roche leadership for a ribbon-cutting at the grand opening, according to seed facts drawn from the announcement.
The center, first announced in March 2025, has grown considerably since its initial pitch. As reported by the Boston Herald, the finished site now spans more than 1 million square feet and has capacity to employ up to 500 people across research, clinical development and data science roles. That marks a dramatic jump from the 30,000-square-foot lease Roche originally described when it announced the project, according to a Roche press release from March 2025, which also confirmed Roche would be the first company to join Harvard's Enterprise Research Campus in Allston.
Roche Group CEO Thomas Schinecker said the Boston investment expands the company's U.S. manufacturing and research and development footprint, per the seed facts. Roche is a Switzerland-based healthcare company, and Genentech operates as its biotechnology subsidiary. The company has said it is investing in scientific talent, new capabilities and infrastructure to strengthen medicine discovery and development, with Roche and Genentech also maintaining locations in North Carolina and Oregon.
A Hub Built Around Cardiovascular and Metabolic Disease
The Allston site will serve as Roche's cardiovascular, renal and metabolism hub, establishing what the company calls a significant end-to-end research and development presence in that disease area, according to the March 2025 announcement from Roche. The center is designed to bring together discovery biologists, clinical experts and computational scientists, and it will lean on active collaborations with academic labs across the Boston-Cambridge area that specialize in cardiovascular, renal and metabolic disease research, per a separate account published on Roche's website.
Manu Chakravarthy, the site's head and Roche's global head of cardiovascular, renal and metabolism product development, marked the milestone in a LinkedIn post announcing the grand opening. The post referenced an inaugural RGIC Boston Science Symposium held in conjunction with the opening, with a scientific program covering CVRM disease biology, human genetics and AI-driven drug discovery, according to Chakravarthy's LinkedIn post.
“…we're celebrating the official Grand Opening of the Roche Genentech Innovation Center (RGIC) Boston.”
Roche has said the new center would bring in AI specialists, discovery researchers and clinical researchers, according to seed facts tied to the opening. The company has previously used artificial intelligence in cancer research to identify targeted treatment approaches and to analyze the effectiveness of new cancer drugs in clinical trials, and it has also worked on efforts to combat antibiotic-resistant bacteria, per the seed facts.
City and State Leaders Frame It as an Economic Win
Mayor Wu said the innovation center will create hundreds of jobs, drive new investment and strengthen Boston's life sciences ecosystem, adding that the city will continue to lead in life science and innovation, according to the seed facts from Thursday's opening. Governor Healey called the expansion a vote of confidence in Massachusetts and its people, saying the state leads the world in life sciences because of collaboration among researchers, workers, universities and companies. Healey added that the center's research will help shape the future of medicine, per the same seed facts.
The expansion comes at an unusual moment for Boston's life sciences real estate market, where both inventory and vacancy rates have climbed to the highest levels among major biotech markets nationally, according to the Boston Business Journal. Even so, that outlet described Roche's roughly 100,000-square-foot lease at the Harvard campus as among the largest life sciences deals in the region. Separate reporting from Boston Real Estate Times put the footprint growth at 30,000 to 100,000 square feet, with the expansion delivered in phases beginning in mid-2026.
Part of a Broader Roche Dealmaking Push
The Boston buildout follows a string of moves by Roche to bulk up its cardiovascular, renal and metabolism pipeline, including a partnership with Alnylam and the $2.7 billion acquisition of Carmot Therapeutics, according to Fierce Biotech. That outlet also noted Roche's roughly $1.4 billion investment in a Basel research and development center with about 1,000 laboratory and office workplaces, offering a point of comparison for the scale of the company's Boston ambitions.
Roche has said it employs more than 25,000 people in the United States and has invested $11 billion domestically over the past decade, according to the company's own March 2025 announcement. The Allston center becomes the latest and largest piece of that U.S. footprint, positioned inside a Harvard-led development that Roche was the first company to join.
